Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network

被引:0
|
作者
Conover, Mitchell M. [1 ,2 ]
Albogami, Yasser [1 ,3 ]
Hardin, Jill [1 ,2 ]
Reich, Christian G. [1 ,4 ]
Ostropolets, Anna [1 ,2 ,5 ]
Ryan, Patrick B. [1 ,2 ,5 ]
Observational Hlth Data Sci and Informatics OHDSI Res Network
机构
[1] Observat Hlth Data Sci & Informat, New York, NY 10032 USA
[2] Johnson & Johnson, Observat Hlth Data Analyt, Titusville, NJ 08560 USA
[3] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia
[4] IQVIA, Real World Solut, Cambridge, MA USA
[5] Columbia Univ, Dept Biomed Informat, New York, NY USA
关键词
chronic lower respiratory disease; common data model; glucagon-like peptide 1 receptor agonists; pharmacoepidemiology; real world data; real world evidence; reliability; replicability; reproducibility; transparency; REPRODUCIBILITY; CALIBRATION; BALANCE;
D O I
10.1002/pds.70087
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
IntroductionThe aim of this study is to use observational methods to evaluate reliability of evidence generated by a study of the effect of glucagon-like peptide 1 receptor agonists (GLP-1RA) on chronic lower respiratory disease (CLRD) outcomes among Type-2 diabetes mellitus (T2DM) patients.Research Design and MethodsWe independently reproduced a study comparing effects of GLP-1RA versus dipeptidyl peptidase-4 inhibitors (DPP4-i) on CLRD outcomes among patients with T2DM and prior CLRD. We reproduced inputs and outputs using the original study data (national administrative claims) and evaluated the robustness of results in comparison to alternate design/analysis decisions. To evaluate generalizability, we applied an analysis protocol and conducted a meta-analysis across a research network that includes a diverse array of populations and data sources. We also produced additional analyses evaluating individual drugs within the GLP-1RA class and CLRD outcomes.ResultsWe confirmed alignment of study inputs and outputs and closely reproduced effect estimates and sensitivity analyses. Adjusted effect estimates were robust to empirical calibration. Network meta-analysis confirmed original findings but indicated weaker effects than originally published. Meta-analysis of drugs within the GLP-1RA class against DPP4-i provided evidence that effects vary within the GLP-1RA class, indicating stronger effects for exenatide and weaker effects of dulaglutide.ConclusionsThis study supports and establishes the reliability of the original study by (1) producing consistent findings in a range of alternate databases and populations, (2) demonstrating effects for multiple drugs within the GLP-1RA class, and (3) independently confirming the reproducibility of the original study and its findings. This reliability evaluation provides the beginnings of a broader framework for using standardized tools and distributed data networks to systematically interrogate the reliability of findings generated using observational data.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Glucagon-like peptide-1 receptor agonists decreases albuminuria in overweight patients with type 2 diabetes
    Bulum, T.
    Blaslov, K.
    Tomic, M.
    Duvnjak, L.
    DIABETOLOGIA, 2015, 58 : S532 - S533
  • [22] Glucagon-Like Peptide-1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes
    Kuo, Chia-Chih
    Chuang, Min-Hsiang
    Li, Chun-Hsien
    Tsai, Ya-Wen
    Huang, Po-Yu
    Kuo, Hsing-Tao
    Lai, Chih-Cheng
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (07) : 1163 - 1174
  • [23] Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes
    Storgaard, Heidi
    Cold, Frederik
    Gluud, Lise L.
    Vilsboll, Tina
    Knop, Filip K.
    DIABETES OBESITY & METABOLISM, 2017, 19 (06): : 906 - 908
  • [24] Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes
    Dankner, Rachel
    Murad, Havi
    Agay, Nirit
    Olmer, Liraz
    Freedman, Laurence S.
    JAMA NETWORK OPEN, 2024, 7 (01) : E2350408
  • [25] Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists
    Foer, Dinah
    Beeler, Patrick E.
    Cui, Jing
    Karlson, Elizabeth W.
    Bates, David W.
    Cahill, Katherine N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (07) : 831 - 840
  • [26] Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
    Harris, Kira B.
    McCarty, Delilah J.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (01) : 3 - 18
  • [27] Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use
    Rossing, Peter
    Agarwal, Rajiv
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Ruilope, Luis M.
    Fonseca, Vivian
    Umpierrez, Guillermo E.
    Caramori, Maria Luiza
    Joseph, Amer
    Lambelet, Marc
    Lawatscheck, Robert
    Bakris, George L.
    DIABETES OBESITY & METABOLISM, 2023, 25 (02): : 407 - 416
  • [28] Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes
    Wester, Axel
    Shang, Ying
    Grip, Emilie Toresson
    Matthews, Anthony A.
    Hagstrom, Hannes
    GUT, 2024, 73 (05) : 835 - 843
  • [29] Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects
    Sloan, Lance A.
    JOURNAL OF DIABETES, 2019, 11 (12) : 938 - 948
  • [30] Novel Glucagon-like Peptide 1 Receptor Agonists for Treating Type II Diabetes
    Sabnis, Ram W.
    ACS MEDICINAL CHEMISTRY LETTERS, 2024, 15 (08): : 1182 - 1183